Skip to main content

Table 3 Response to treatment

From: Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network

 

Clinical response

(RECIST)

N = 29

No. (%)

Biochemical response (Chromogranin A)

N = 25

No. (%)

Symptomatic response

N = 15

No. (%)

Progression

2 (6.9)

2 (8.0)

 

No change

20 (69.0)

11 (44.0)

6 (40.0)

Partial response

7 (24.1)

8 (32.0)

6 (40.0)

Complete response

-

4 (16.0)

3 (20.0)

Overall response

7 (24.1)

(95% CI 8.3-39.9)

12 (48.0)

(95% CI 28.0-68.0)

9 (60.0)

  1. RECIST = Response Evaluation Criteria in Solid Tumors